Minerva Neurosciences (NERV) Net Income (2013 - 2026)
Minerva Neurosciences posted quarterly Net Income of -$16.0 million for Q1 2026, down 328.4% year-on-year from $7.0 million in Q1 2025, and down 261.71% on a QoQ basis from -$4.4 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Net Income data on file, last reported at -$16.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 328.4% year-over-year to -$16.0 million; the trailing twelve-month figure through Mar 2026 stood at -$26.5 million (down 46.98% YoY), and the FY2025 full-year result was -$14.2 million, up 31.21% from the prior year.
- Net Income for Q1 2026 stood at -$16.0 million, down from -$4.4 million in the prior quarter.
- Across five years, Net Income topped out at -$2.7 million in Q3 2025 and bottomed at -$16.0 million in Q1 2026.
- The 5-year median for Net Income is -$5.0 million (2023), against an average of -$5.7 million.
- The widest annual swing landed in 2022, when Net Income surged 77.67%; it then sank 328.4% in 2026.
- A 5-year view of Net Income shows it stood at -$4.8 million in 2022, then sank by 42.75% to -$6.8 million in 2023, then soared by 37.14% to -$4.3 million in 2024, then decreased by 3.56% to -$4.4 million in 2025, then slumped by 261.71% to -$16.0 million in 2026.
- The last three Net Income figures came in at -$16.0 million (Q1 2026), -$4.4 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -16.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.04 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.92 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -6.81 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -4.15 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -4.77 Mn |
| Sep 30, 2022 | -5.03 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -7.98 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.51 Mn |
| Jun 30, 2021 | -8.96 Mn |
| Mar 31, 2021 | -7.50 Mn |
| Dec 31, 2020 | -7.30 Mn |
| Sep 30, 2020 | -8.09 Mn |
| Jun 30, 2020 | 29.53 Mn |
| Mar 31, 2020 | -12.14 Mn |
| Dec 31, 2019 | -32.16 Mn |
| Sep 30, 2019 | -13.96 Mn |
| Jun 30, 2019 | -12.47 Mn |
| Mar 31, 2019 | -15.82 Mn |
| Dec 31, 2018 | -13.63 Mn |
| Sep 30, 2018 | -12.01 Mn |
| Jun 30, 2018 | -12.52 Mn |
| Mar 31, 2018 | -12.33 Mn |
| Dec 31, 2017 | -9.10 Mn |
| Sep 30, 2017 | -11.54 Mn |
| Jun 30, 2017 | -9.59 Mn |
| Mar 31, 2017 | -10.43 Mn |
| Dec 31, 2016 | -10.40 Mn |
| Sep 30, 2016 | -8.16 Mn |
| Jun 30, 2016 | -5.23 Mn |
| Mar 31, 2016 | -8.03 Mn |
| Dec 31, 2015 | -8.16 Mn |
| Sep 30, 2015 | -5.67 Mn |
| Jun 30, 2015 | -6.30 Mn |
| Mar 31, 2015 | -6.11 Mn |
| Dec 31, 2014 | -7.45 Mn |
| Sep 30, 2014 | -27.17 Mn |
| Jun 30, 2014 | -21.10 Mn |
| Mar 31, 2014 | -2.62 Mn |
| Dec 31, 2013 | -2.04 Mn |
| Sep 30, 2013 | -482,000.00 |
| Jun 30, 2013 | -376,166.00 |